TheraRadar
← Back
Data updated: Jun 28, 2026

PIERRE FABRE

Specialty
OncologyDermatologyInfectious Disease Execution: Good

PIERRE FABRE is a specialty pharmaceutical company focused on Oncology, Dermatology, Infectious Disease.

1994
Since
2
Drugs
-
Trials
0
New Drugs (2yr)

PIERRE FABRE at a Glance

  • Fast trial execution (12 months median completion)

PIERRE FABRE's Key Drugs

PIERRE FABRE's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

PIERRE FABRE's Recent FDA Approvals

New NDA/BLA approvals for PIERRE FABRE over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

PIERRE FABRE's Therapeutic Areas

PIERRE FABRE's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Dermatology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 73%
1 drugs Phase 3: 5 Phase 2: 5 Phase 1: 9
Dermatology 13%
0 drugs Phase 3: 2
Infectious Disease 6%
0 drugs Phase 3: 1
Respiratory 5%
0 drugs Phase 2: 1 Phase 1: 1
Immunology 3%
0 drugs Phase 2: 1

PIERRE FABRE's Top Competitors

PIERRE FABRE's closest competitors by therapeutic-area and drug-target overlap include Pfizer, GSK, and Novartis. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Pfizer big-pharma
Oncology, Infectious Disease, Immunology, Dermatology
GSK big-pharma
Respiratory, Infectious Disease, Oncology, Immunology
Novartis big-pharma
Oncology, Respiratory, Immunology
Merck big-pharma
Oncology, Infectious Disease, Respiratory
PHARMACIA AND UPJOHN big-pharma
Dermatology, Infectious Disease, Respiratory, Immunology

PIERRE FABRE Pipeline Snapshot

PIERRE FABRE has 25 active clinical programs from ClinicalTrials.gov — 8 Phase 3, 7 Phase 2 and 10 Phase 1.

8
Phase 3
7
Phase 2
10
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 10/12 completed
  • • Speed: 12 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges